Americans generally would like to spend less money on health care. One way that this can be and will be accomplished is through the continued use and expanded use of generic drugs.
It is very rare for a year to go exactly as analysts and investors might expect. After all, predicting a move a day or a week out is hard enough — and…
October 13, 2016: Markets opened lower Thursday following a weaker view on China’s trade balance joined with worries about the Fed and third-quarter earnings leave investors with the jitters. Citi, Wells Fargo,…
The September 30 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest was mixed.
October 6, 2016: Markets opened slightly lower Thursday and tracked close to the break-even line for much of the day. Tomorrow’s report on non-farm payrolls for September is the week’s big data…
September 29, 2016: Markets opened slightly higher again Thursday following Wednesday’s announced agreement among OPEC members to rein in production. Comments various Fed officials talking a rate hike later this year cooled…
The September 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has increased.
September 26, 2016: Markets opened lower again Monday and only the recently added real-estate sector traded higher on the day. Crude oil prices were up on hopes for an agreement this week…
Pfizer shares traded down marginally Monday morning after the company announced that it will abandon its plan to split into two companies.
Chris Lange While the polls have the race pretty tight, one thing is for sure: a victory by Donald Trump would favor a far different group of stocks than a victory by Hillary Clinton.
The volatility in the markets have shaken some of the top dividend leaders and may be giving long-term investors a great buying opportunity.
Despite recent market headwinds and volatility, there are strong underlying fundamentals among the large cap pharmaceuticals that are continuing to drive them forward.
The August 31 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has significantly decreased.
In a new research report, Baird notes two biotech companies in its research coverage universe that may be considered speculative takeover targets, and a third is a possible target as well.
The August 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has significantly decreased.
